CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of multiple abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress, from July 10-12, 2021. The details are as follows: Title: A single on-demand treatment with orally administered KVD900 [...]